Gilead Sciences, Inc. $GILD Stock: Robeco Institutional Asset Management B.V. Trims Stake

Robeco Institutional Asset Management B.V. lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.5% during the 3rd quarter, Holdings Channel reports. The firm owned 3,442,819 shares of the biopharmaceutical company’s stock after selling 17,074 shares during the quarter. Gilead Sciences makes up about 0.6% of Robeco Institutional Asset Management B.V.’s holdings, making the stock its 29th biggest position. Robeco Institutional Asset Management B.V.’s holdings in Gilead Sciences were worth $513,152,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. BlackRock Inc. purchased a new position in shares of Gilead Sciences during the second quarter valued at about $15,393,785,000. State Street Corp increased its holdings in shares of Gilead Sciences by 2.3% in the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after purchasing an additional 1,357,967 shares during the last quarter. Amundi increased its holdings in shares of Gilead Sciences by 10.7% in the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock worth $1,468,836,000 after purchasing an additional 1,018,976 shares during the last quarter. Legal & General Group Plc bought a new stake in shares of Gilead Sciences in the second quarter worth about $1,316,606,000. Finally, Deutsche Bank AG purchased a new stake in shares of Gilead Sciences in the second quarter worth about $918,387,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $156.51 on Wednesday. The firm has a market capitalization of $194.06 billion, a price-to-earnings ratio of -58.62 and a beta of 0.31. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The business has a 50 day simple moving average of $148.01 and a 200-day simple moving average of $137.50. Gilead Sciences, Inc. has a 1 year low of $114.02 and a 1 year high of $160.51.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. Gilead Sciences’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.01 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post -0.47 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.1%. The ex-dividend date was Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is presently -122.85%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on GILD shares. Truist Financial increased their price target on Gilead Sciences from $150.00 to $158.00 and gave the company a “buy” rating in a research note on Wednesday, October 7th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price target on shares of Gilead Sciences in a report on Thursday, October 8th. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Barclays reduced their price objective on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 29th. Finally, HSBC upped their price objective on Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $159.63.

Insider Activity at Gilead Sciences

In related news, CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the sale, the chief financial officer directly owned 161,096 shares of the company’s stock, valued at $25,166,417.12. This represents a 1.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the sale, the insider directly owned 118,234 shares in the company, valued at $16,273,727.76. This trade represents a 19.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 111,000 shares of company stock worth $15,877,860 in the last three months. 0.30% of the stock is owned by insiders.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Ulcerative colitis trial success strengthens the pipeline. Gilead reported positive Phase 2 SWIFT results for emvistegrast, an oral treatment for active ulcerative colitis. The data were described as “highly competitive,” supporting management’s strategy to expand into immunology and inflammatory bowel disease. Success in a large market could diversify Gilead beyond its HIV franchise. Gilead’s highly competitive mid-stage ulcerative colitis data validate I&I push
• Positive Sentiment: Bank of America raised its price target and maintained a Buy rating. The target increased from $168 to $172, implying roughly 10% upside from the referenced price and signaling confidence in Gilead’s earnings outlook and pipeline prospects.
• Positive Sentiment: Recent FDA decisions add commercial catalysts. Gilead received approval for the Bixlenvo HIV regimen, a first-line label expansion for Trodelvy in metastatic triple-negative breast cancer, and approval for Hepcludex in chronic hepatitis delta. The company will also present 28 HIV and antiviral research findings at IDWeek 2026, potentially providing additional clinical updates. How Investors Are Reacting To Gilead Sciences FDA Drug Approvals
• Positive Sentiment: Analyst and quantitative sentiment improved. Gilead was upgraded to Zacks Rank #2 (Buy), reflecting improving expectations for earnings prospects. Separately, 43 ETFs added Gilead shares, indicating some institutional demand. Gilead rating upgrade to Buy
• Neutral Sentiment: Investors are weighing acquisitions against Gilead’s dependable HIV cash flow. Biktarvy and other HIV products continue to support recurring revenue and the dividend, but acquisitions such as Arcellx and Tubulis have increased research and integration costs. Gilead reportedly recorded a substantial trailing loss as it absorbs those investments.
• Negative Sentiment: ETF selling and near-term profitability concerns could limit gains. ETFs were also reported as net sellers of Gilead on October 16, while coverage noted that the ulcerative-colitis trial win initially failed to lift the stock. Investors may remain focused on acquisition-related expenses and the path back to sustainable positive earnings. ETFs Are Net Sellers of Gilead Sciences

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.